Form 4: Medicus Pharma Director Granted Stock Options

Medicus Pharma Ltd. director Barry Fishman was granted 25,000 stock options with an exercise price of $1.80, vesting quarterly over one year.

Summary

• Barry Fishman, a Director and 10% Owner of Medicus Pharma Ltd. (MDCX), was granted stock options.
• The grant occurred on December 16, 2025.
• He received 25,000 stock options, each with an exercise price of $1.80.
• These options are scheduled to vest quarterly in four equal installments over one year.
• The options have an expiration date of December 16, 2030.
• Following this transaction, Barry Fishman directly beneficially owns 25,000 derivative securities (stock options).

Sentiment

Score: 6

Explanation: Slightly positive, as it indicates alignment of interests between a director/significant owner and the company's future performance, a common incentive mechanism.

Positives

• Granting stock options to a director aligns their interests with those of shareholders, incentivizing long-term company performance.
• The director's continued ownership of 10% of the company, in addition to the options, demonstrates significant commitment.

Negatives

• Potential for future dilution of existing shareholders if the options are exercised, although the amount is relatively small (25,000 shares).

Risks

• The value of the stock options is dependent on the future market price of Medicus Pharma Ltd. common shares. If the share price does not exceed the exercise price of $1.80, the options may expire worthless.
• Exercise of these options in the future will result in an increase in the number of outstanding common shares, potentially diluting the ownership percentage of existing shareholders.

Future Outlook

The granted stock options are scheduled to vest quarterly over one year, indicating a future increase in the director's exercisable equity stake in the company.

Management Comments

• The option was granted on December 16, 2025.
• The option is scheduled to vest quarterly in four equal installments over one year.

Industry Context

The grant of stock options to a director is a common practice in the pharmaceutical and biotechnology industries, used to incentivize long-term performance and align management interests with shareholder value creation. This type of compensation is a standard component of executive and director remuneration packages.

Comparison to Industry Standards

• Stock option grants are a standard form of equity compensation for directors and executives across various industries, including pharmaceuticals.
• The vesting schedule of quarterly installments over one year is a common approach to retain talent and ensure continued engagement.
• The exercise price of $1.80 would typically be set at or above the market price on the grant date, which is standard practice for incentive stock options.

Related Party Transactions

• The grant of 25,000 stock options to Barry Fishman, a Director and 10% Owner, constitutes a related party transaction.

Stakeholder Impact

• Shareholders: Potential for minor dilution if options are exercised, but also potential for increased long-term value creation due to aligned director incentives.

Next Steps

• The stock options will vest quarterly over the next year, starting from December 16, 2025.
• Barry Fishman may choose to exercise these options at any point between their vesting date and the expiration date of December 16, 2030, assuming the share price is favorable.

Key Dates

Keywords

Medicus Pharma, MDCX, stock option, insider transaction, director compensation, beneficial ownership, equity grant, Form 4